Clinical manifestations and treatment of mucopolysaccharidosis type I patients in Latin America as compared with the rest of the world
Open Access
- 4 May 2011
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 34 (5) , 1029-1037
Abstract
Background Mucopolysaccharidosis I (MPS I) comprises a spectrum of clinical manifestations and is divided into three phenotypes reflecting clinical severity: Hurler, Hurler‐Scheie, and Scheie syndromes. There may be important variations in clinical manifestations of this genetic disease in patients residing in different regions of the world. Methods Using data from the MPS I Registry (as of September 2009), we evaluated patients from Latin America (n = 118) compared with patients from the rest of the world [ROW (n = 727)]. Results Phenotype distribution differed among patients in Latin America compared to ROW (Hurler 31 vs. 62%, Hurler‐Scheie 36 vs. 21%, Scheie 10 vs. 11%, and unknown 22 vs. 6%). The frequency of certain symptoms, such as cardiac valve abnormalities, sleep impairment, and joint contractures, also differed between Latin America and ROW for some phenotypes. Median age at MPS I diagnosis was earlier in the ROW than Latin America for all phenotypes, and age at first treatment for Hurler and Hurler‐Scheie patients was also earlier in the ROW. Hurler patients in Latin America showed a gap of 3.1 years between median ages of diagnosis and first treatment compared to only 0.5 years in the ROW. Treatment allocation in Latin America compared to ROW was as follows: enzyme replacement therapy (ERT) only, 80 vs. 45%; hematopoietic stem cell transplantation (HSCT) only, 0.9 vs. 27%; both ERT and HSCT, 0 vs. 16%; and neither treatment, 19 vs. 13%. Conclusion These data highlight important differences in MPS I patients between Latin America and ROW in terms of phenotypic distribution, clinical manifestations, and treatment practices.Keywords
This publication has 21 references indexed in Scilit:
- The MPS I registry: Design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type IMolecular Genetics and Metabolism, 2007
- Analysis of factors affecting development of carpal tunnel syndrome in patients with Hurler syndrome after hematopoietic cell transplantationBone Marrow Transplantation, 2007
- A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 yearsMolecular Genetics and Metabolism, 2007
- Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndromeJournal of Inherited Metabolic Disease, 2006
- Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndromeBone Marrow Transplantation, 2006
- Clinical presentation and follow‐up of patients with the attenuated phenotype of mucopolysaccharidosis type IActa Paediatrica, 2005
- The first 5years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis IExpert Opinion on Pharmacotherapy, 2005
- Laronidase Treatment of Mucopolysaccharidosis IBioDrugs, 2005
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)The Journal of Pediatrics, 2004
- Can mucopolysaccharidosis type I disease severity be predicted based on a patient’s genotype? A comprehensive review of the literatureGenetics in Medicine, 2003